| Sucampo Pharmaceuticals, Inc. | |
| Industry: | Pharmaceutical industry |
| Fate: | Acquired by Mallinckrodt |
| Hq Location: | Rockville, Maryland |
| Key People: | Peter Greenleaf Andrew P. Smith (CFO) |
| Products: | Amitiza |
| Revenue: | $230 million (2016) |
| Net Income: | $18 million (2016) |
| Assets: | $520 million (2016) |
| Equity: | $167 million (2016) |
| Num Employees: | 139 (2017) |
| Footnotes: | [1] |
Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders.[1] In 2018, the company was acquired by Mallinckrodt.
Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated.[1]
The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.[1]
In January 2006, the company received approval from the Food and Drug Administration for Amitiza.[2]
In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.[3]
In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.[4]
In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.[5]
In April 2017, the company acquired Vtesse.[6]
In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.[7]